Abstract
A number of novel furo[2,3-b]quinoline derivatives were designed and synthesized by introducing different substituted anilines and phenols to C4-position of furo[2,3-b]quinoline. All target compounds were evaluated in vitro against two human breast cancer cell lines (MCF-7 and MDA-MB-231) and one normal breast cell (MCF-10A) by MTT (3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium broide, Thiazolyl blue) method. Most derivatives showed significant cytotoxic activity on the two breast cancer cells with IC50 values in the range of (5.60-26.24 μM) and a certain selectivity, especially in the inhibition of MDA-MB-231. More notably, they were less toxic to normal breast cell (MCF-7-10A). Compound I7 could be considered as an ideal selective candidate for further study. Mechanism studies showed that I7 could inhibit the proliferation of cells by arresting MDA-MB-231 cell cycle at G2/M phase. Overall, as a novel furo[2,3-b]quinoline derivative, I7 exhibited an excellent inhibitory effect in MDA-MB-231 cell and was worthy of in-depth study.
Keywords: Furo[2, 3-b]quinolone, breast cancer, design and synthesis, cytotoxic activity, topoisomerase II, MTT.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Development of Furo[2,3-b]quinoline Derivatives with Anti-Breast Cancer Property by Targeting Topoisomerase II
Volume: 21 Issue: 12
Author(s): Ying Wang, Na Li, Neng Jiang, Li Chen*Jianbo Sun*
Affiliation:
- Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009,China
- Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009,China
Keywords: Furo[2, 3-b]quinolone, breast cancer, design and synthesis, cytotoxic activity, topoisomerase II, MTT.
Abstract: A number of novel furo[2,3-b]quinoline derivatives were designed and synthesized by introducing different substituted anilines and phenols to C4-position of furo[2,3-b]quinoline. All target compounds were evaluated in vitro against two human breast cancer cell lines (MCF-7 and MDA-MB-231) and one normal breast cell (MCF-10A) by MTT (3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium broide, Thiazolyl blue) method. Most derivatives showed significant cytotoxic activity on the two breast cancer cells with IC50 values in the range of (5.60-26.24 μM) and a certain selectivity, especially in the inhibition of MDA-MB-231. More notably, they were less toxic to normal breast cell (MCF-7-10A). Compound I7 could be considered as an ideal selective candidate for further study. Mechanism studies showed that I7 could inhibit the proliferation of cells by arresting MDA-MB-231 cell cycle at G2/M phase. Overall, as a novel furo[2,3-b]quinoline derivative, I7 exhibited an excellent inhibitory effect in MDA-MB-231 cell and was worthy of in-depth study.
Export Options
About this article
Cite this article as:
Wang Ying , Li Na , Jiang Neng , Chen Li *, Sun Jianbo *, Development of Furo[2,3-b]quinoline Derivatives with Anti-Breast Cancer Property by Targeting Topoisomerase II, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (12) . https://dx.doi.org/10.2174/1871520620999201103201348
DOI https://dx.doi.org/10.2174/1871520620999201103201348 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymer Conjugated Gold Nanoparticles in Biomedical Applications
Current Medicinal Chemistry A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility
CNS & Neurological Disorders - Drug Targets Genomic Instability and Cancer
Current Molecular Medicine Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications
Current Drug Targets Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Therapeutic Antibodies
Current Molecular Medicine Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science Towards Improved Lossless Compression for Mammogram Images using Differential Pulse Code Modulation
Current Medical Imaging Editorial
Current Molecular Medicine In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid
Current Neuropharmacology Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals Pathology of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Safety of Nanoparticles in Medicine
Current Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry